LOL. NWBO is toast and everybody knows it. They are morphing into a CDMO that will be worth a few hundred million.
NVCR will live or die by the lung cancer trial. If that fails they can continue to eak out an existence, but no real upside. If it works, they can say bye-bye to tiny markets like GBM.
Aren't you aware that NVCR is running five pivotal trials (brain mets from NSCLC, NSCLC, rGBM, ovarian and pancreatic) that will readout in the next few years? As for NWBO, I very much doubt we will ever see data from them, or it will be utter bull.